All In Biotech

Drug Trial Radar · NCT06649708

HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies

A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies

Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 30, 2024

Primary completion

Oct 31, 2025

Study completion Oct 31, 2027

Sponsor

Sponsor type
Industry
First posted
Oct 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will consist of a dose-escalation and dose-expansion component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and to evaluate the preliminary antitumor activity of HX044. HX044 is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authorities for commercial purposes. This is the first study in which HX044 will be given to humans. The study drug has been tested in animals and was found to be well-tolerated with minimal side effects.

Conditions

  • Advanced Solid Tumor Malignancies

Interventions

  • HX044Drug

    Conventional dose-escalation design with 3+3 cohort size. All administered on a Q3 weekly basis. Dose escalation will be based on the absence of DLTs during the 21-day DLT evaluation after a review of safety data by the Safety Review Escalation Committee. Subjects will continue on study treatment until the subject develops an intolerable toxicity, withdraws consent, develops progression of disease, death, lost to follow-up, start of new anticancer treatment or up to study treatment duration of 24 months, whichever comes first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants experiencing Adverse Events (AEs)Time frame: All AEs up to 90(±7)days after the last dose of study treatment
  2. Number of Participants With Dose-Limiting Toxicities(DLT) of HX044Time frame: At the end of Cycle 2(each cycle is 21±3 days)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Blacktown Hospital

    Blacktown, New South Wales, Australia · Not yet recruiting

  • Icon Cancer Centre Wesley

    Auchenflower, Queensland, Australia · Recruiting

  • Cabrini Health Limited

    Malvern, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.